FindTrial
Sign In

The efficacy molecular mechanisms of Bu-qi-yi-jing-sheng-xue therapy for children with beta-thalassemia

The efficacy molecular mechanisms of Bu-qi-yi-jing-sheng-xue therapy for children with beta-thalassemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15007050
Enrollment
Unknown
Registered
2015-08-27
Start date
2011-03-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beta-thalassemia

Interventions

fomula medicine:oral Astragalus membranaceus (Radix Astragali), Codonopsis pilosula (Radix Codonopsis), Tortoise plastron (Tortoise) granules
Radix Astragali :oral Astragalus membranaceus (Radix Astragali) granules
placebo control :oral placebo granules

Sponsors

Guangzhou hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 2 Years

Inclusion criteria

Inclusion criteria: (1) 2 to 18 years old; (2) which have genetic testing results fulfils the diagnostic criteria of beta-thalassemia intermedia; (3) wihout any blood transfusion other anti-anemia treatment in last 12 months; (4) Hb 60g/L-100g/L before recruiting; (5) volunteer with informed consent.

Exclusion criteria

Exclusion criteria: (1) with any disease of cardiovascular tem, liver, kidney, alimentary canal, endocrine tem or immune tem or with other primary disease of primary disease; (2) atopy or allergic to 2 or more drugs; (3) with any mental disease or psychological disorder or bad compliance.

Countries

China

Contacts

Public ContactLU Zhuo-Ming
739835365@qq.com+86 13416182231

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026